Table of Contents

Serum biomarkers for neurodegeneration

Objectives

Identify novel serum biomarkers for neurodegeneration that allow accurate diagnosis of Alzheimer's disease (AD) in Hispanic and non-Hispanic white populations (Specific Aims ).

Data

  1. Six proteins were measured in blood samples of ~1200 Hispanic and ~500 non-Hispanic white participants. Covariates include gender, education, and age.
  2. The cognitive status of participants were assessed in several visits over years. The number of visits and time intervals between visits vary across participants.

Collaborators

Dr. Sudha Seshadri, the Founding director of the Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, and Dr. Mitzi Gonzales from the Department of Neurology at University of Texas Health Science Center in San Antonio. This study is supported by Texas Alzheimer's Research and Care Consortium (TARCC).

Analysis

  1. Linear models.
  2. Regularized regression, e.g., the LASSO and FeaLect.
  3. Hidden Markov Models (HMM).
  1. Eagan, Danielle E., et al. “Elevated serum C-reactive protein relates to increased cerebral myoinositol levels in middle-aged adults.” Cardiovascular psychiatry and neurology 2012 (2012).